International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia

No abstract is available for this paper.

• Publication year

  2005

• Venue

  European Journal of Clinical Microbiology and Infectious Diseases

• Publication date

  2005-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10096-005-0024-8PMID 16261306
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Micafungin

  2012cited by this paper
• Candida biofilms: antifungal resistance and emerging therapeutic options.

  2004cited by this paper
• Candidemia in a Brazilian tertiary care hospital: species distribution and antifungal susceptibility patterns.

  2004cited by this paper
• Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates

  2004cited by this paper
• Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002

  2004cited by this paper
• A one-year survey of candidemia in Belgium in 2002

  2004cited by this paper
• A Multicenter, Open-Label Clinical Study of Micafungin (FK463) in the Treatment of Deep-seated Mycosis in Japan

  2004cited by this paper
• Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

  2004cited by this paper
• Guidelines for treatment of candidiasis.

  2004cited by this paper
• High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study

  2004cited by this paper
• Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program

  2004cited by this paper
• Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.

  2004cited by this paper
• Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

  2004cited by this paper
• Caspofungin: the first in a new class of antifungal agents.

  2003cited by this paper
• Voriconazole Salvage Treatment of Invasive Candidiasis

  2003cited by this paper
• A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

  2003cited by this paper
• Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States

  2003cited by this paper
• Amphotericin B: time for a new "gold standard".

  2003cited by this paper
• Candidemia in Finland, 1995–1999

  2003cited by this paper
• The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy

  2003cited by this paper
• Antifungal agents: mechanisms of action.

  2003cited by this paper
• The global epidemiology of invasive Candida infections--is the tide turning?

  2003cited by this paper
• Voriconazole treatment for less-common, emerging, or refractory fungal infections.

  2003cited by this paper
• A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

  2003cited by this paper
• Epidemiology of Candida species infections in critically ill non-immunosuppressed patients.

  2003cited by this paper
• Echinocandin antifungal drugs.

  2003cited by this paper
• Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

  2002cited by this paper
• Secular Trends of Candidemia Over 12 Years in Adult Patients at a Tertiary Care Hospital

  2002cited by this paper
• Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

  2002cited by this paper
• Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins

  2002cited by this paper
• Comparison of caspofungin and amphotericin B for invasive candidiasis.

  2002cited by this paper
• Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey.

  2001cited by this paper
• Mortality and costs of acute renal failure associated with amphotericin B therapy.

  2001cited by this paper
• Hitting a new target with echinocandins. Why chase something else?

  2001cited by this paper
• Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis.

  2001cited by this paper
• Caspofungin: the first of a new class of antifungal agents.

  2001cited by this paper
• Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998

  2000cited by this paper
• Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

  2000cited by this paper
• Antifungal resistance in non- albicans Candida species.

  1999cited by this paper
• High rate of non-albicans candidemia in Brazilian tertiary care hospitals.

  1999cited by this paper
• National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units.

  1999cited by this paper
• International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).

  1999cited by this paper
• Role of newer azoles in surgical patients.

  1999cited by this paper
• Predictors of adverse outcome in cancer patients with candidemia.

  1998cited by this paper
• Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients

  1997influential reference
• Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature.

  1996cited by this paper
• Epidemiology of nosocomial fungal infections, with emphasis on Candida species.

  1995cited by this paper
• A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

  1994cited by this paper
• A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia

  1994cited by this paper
• Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance

  1984cited by this paper
• Development of Resistance to Amphotericin B in Candida lusitaniae Infecting a Human

  1979cited by this paper
• Infectious Diseases Society of America

  1969cited by this paper

• Candida parapsilosis Endocarditis of the Native Tricuspid Valve in a Patient Without Common Risk Factors

  2025cites this paper
• Challenges in the Diagnosis and Treatment of Invasive Candidiasis in India

  2024cites this paper
• Antifungal Combinations against Candida Species: From Bench to Bedside

  2022cites this paper
• Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.

  2022cites this paper
• Perioperative anidulafungin combined with triazole prophylaxis for the prevention of early invasive candidiasis in lung transplant recipients

  2021cites this paper
• Role of Antifungal Combinations in Difficult to Treat Candida Infections

  2021cites this paper
• Echinocandins

  2021cites this paper
• The current place of echinocandins in the treatment and prophylaxis of invasive fungal infections

  2020cites this paper
• Effectiveness and Safety of Micafungin in Managing Invasive Fungal Infections among Patients in Greece with Hematologic Disorders: The ASPIRE Study

  2019cites this paper
• Characterization of non - albicans Candida species involved in human infections

  2019cites this paper
• Epidemiology and Outcomes of Candidemia in a Referral Center in Tehran

  2019cites this paper
• Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis

  2019cites this paper
• Echinocandins: Their role in the management of Candida biofilms

  2018cites this paper
• Advances in the Treatment of Mycoses in Pediatric Patients

  2018cites this paper
• Micafungin and caspofungin pharmacodynamics in patients with candidemia

  2018cites this paper
• Echinocandins in antifungal pharmacotherapy

  2017cites this paper
• Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients

  2017cites this paper
• Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.

  2016cites this paper
• ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

  2016cites this paper
• Spectrum of Activity, Pharmacology, and Clinical Indications

  2015cites this paper
• A n t i f u n g a l A g e n t s Spectrum of Activity, Pharmacology, and Clinical Indications

  2015cites this paper
• Micafungin in Premature and Non-premature Infants

  2014cites this paper
• Micafungin: an evidence-based review of its place in therapy

  2014cites this paper
• Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study

  2014cites this paper
• Antifungal Therapy for Invasive Fungal Infections

  2014cites this paper
• Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non‐albicans Candida species

  2014cites this paper
• Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents

  2013cites this paper
• Treatment of invasive candidiasis in neutropenic patients: systematic review of randomized controlled treatment trials

  2013cites this paper
• Advances in systemic antifungal therapy.

  2012cites this paper
• Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use

  2012cites this paper
• Micafungin

  2012cites this paper
• Clinical Relevance of In Vitro Resistance of Echinocandins: a Focus on Candida parapsilosis

  2012cites this paper
• Echinocandin Antifungal Drugs in Fungal Infections

  2012cites this paper
• Azole‐resistant Candida spp. – emerging pathogens?

  2012cites this paper
• Micafungin for candidiasis

  2012cites this paper
• Interactions of Yeasts, Moulds, and Antifungal Agents

  2012cites this paper
• Micafungin in haematology

  2012cites this paper
• Chapter 17 – Neonatal Fungal Infections

  2012cites this paper
• Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients

  2012cites this paper
• The Impact of Antifungal Drug Resistance in the Clinic

  2012cites this paper
• Clinical development of micafungin in children and neonates

  2012cites this paper
• Erratum to: Echinocandin antifungal drugs in fungal infections: a comparison

  2012cites this paper
• Utilization Patterns of Caspofungin and Micafungin for Treatment of Invasive Fungal Infections

  2012cites this paper
• [Invasive fungal infection in critically ill patient: role of micafungin].

  2012cites this paper
• Utility of Antifungal Susceptibility Testing and Clinical Correlations

  2012cites this paper
• Evaluation of the Sensititre Yeast One microdilution method for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin.

  2012cites this paper
• 339 – Systemic Antifungal Agents

  2012cites this paper
• Fungal infections in severe acute pancreatitis

  2011cites this paper
• [Antifungal therapy update: new drugs and medical uses].

  2011cites this paper
• Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

  2011cites this paper
• linical breakpoints for the echinocandins and Candida revisited : Integration of olecular , clinical , and microbiological data to arrive at species-specific nterpretive criteria

  2011cites this paper
• In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?

  2011cites this paper
• Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins

  2011cites this paper
• Safety of Micafungin in Pediatric Clinical Trials

  2011cites this paper
• [Echinocandins].

  2011cites this paper
• [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis].

  2011cites this paper
• Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections.

  2011cites this paper
• Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report

  2011cites this paper
• Multilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis

  2011cites this paper
• Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis

  2011cites this paper
• Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study

  2011cites this paper
• Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

  2011cites this paper
• [Echinocandins in children].

  2011cites this paper
• Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study.

  2011cites this paper
• Micafungin use in children

  2011cites this paper
• effi cacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis : a prospective observational study

  2011cites this paper
• Traditional and emerging antifungal therapies.

  2010cites this paper
• Breakthrough Invasive Candidiasis in Patients on Micafungin

  2010cites this paper
• New antifungal agents for the treatment of candidaemia.

  2010cites this paper
• A Clinical Review of Echinocandins in Pediatric Patients

  2010cites this paper
• Echinocandin pharmacodynamics: review and clinical implications.

  2010cites this paper
• Intrapulmonary Pharmacokinetics and Pharmacodynamics of Micafungin in Adult Lung Transplant Patients

  2010cites this paper
• Two Drugs Better Than One? Combination Antifungal Therapy Revisited

  2010cites this paper
• Novel, broad-specrum antimycotic agents: the role of echinocandins today

  2010cites this paper
• Managing Infections in Patients With Hematological Malignancies

  2010cites this paper
• Efficacy and Safety of Micafungin as an Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases

  2010cites this paper
• Micafungin in a nutshell: state of affairs on the pharmacological and clinical aspects of the novel echinocandin

  2010cites this paper
• Epidemiology of invasive candidiasis

  2010cites this paper
• antimycotic agents: the role of echinocandins today

  2010cites this paper
• Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review.

  2010cites this paper
• Echinocandins – Caspofungin, Anidulafungin and Micafungin

  2010cites this paper
• Utilidad clínica de la micafungina en el tratamiento de las candidiasis invasoras en el paciente oncohematológico

  2009cites this paper
• The impact of total bilirubin on plasma micafungin levels in living-donor liver transplantation recipients with severe liver dysfunction.

  2009cites this paper
• Micafungin

  2009cites this paper
• Newer antifungal agents in pediatrics

  2009cites this paper
• Refractory neonatal candidemia and high-dose micafungin pharmacotherapy

  2009cites this paper
• Echinocandins for prevention and treatment of invasive fungal infections

  2009cites this paper
• [Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate].

  2009cites this paper
• Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

  2009cites this paper
• New antifungal agents in pediatric practice.

  2009cites this paper
• Utilidad clínica de la micafungina en el tratamiento de las candidiasis invasoras en el neonato

  2009cites this paper
• Chapter 4 Fungal and Parasitic Infections

  2009cites this paper
• [Micafungin in pediatric and adolescent patients].

  2009cites this paper
• Fungal and Parasitic Infections

  2009cites this paper
• Activity of Anidulafungin in a Murine Model of Candida krusei Infection: Evaluation of Mortality and Disease Burden by Quantitative Tissue Cultures and Measurement of Serum (1,3)-β-d-Glucan Levels

  2009cites this paper
• Pharmacoeconomic Analysis of Micafungin (Mycamine) 100 mg and 150 mg Daily In the Treatment of Candidemia.

  2009cites this paper
• pharmacotherapy of Candida Infections with echinocandins

  2009cites this paper
• Antimikrobielle Therapie

  2009cites this paper
• Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation.

  2009cites this paper
• Clinical effects of micafungin, a novel echinocandin antifungal agent, on systemic fungal infections in surgery, emergency, and intensive-care medicine: evaluation using the AKOTT algorithm

  2009cites this paper